The Effects of Supplement French Pine Bark Extract (Oligopin) on LDL and HDL in Selected Women with Type II Diabetic

Diabetes is one of the most common chronic diseases in the world, affecting more than 100 million people worldwide annually. It has been estimated that the rate of diabetes incidence will increase from 463 million in 2019 to 578 million by 2030. The development of acute and chronic complications can be prevented by controlling risk factors in these patients. This study was conducted to evaluate the concomitant effect of French maritime pine bark extract (under the brand name of chr('39')Oligopinchr('39')) on the control of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) as risk factors for cardiovascular disease in females with type II diabetes.

This randomized, double-blind clinical trial was performed on 30 females with type II diabetes using a placebo for comparative purposes. The participants were divided into two groups (n=15 each), and received concomitant supplement or placebo, in addition to medical treatment, under the supervision of their physician for 6 weeks. Laboratory sampling was performed at the baseline and after the intervention. The normality of data distribution was determined by the Kolmogorov-Smirnov test. The collected data were analyzed using a paired t-test (P <0.05).

. The results of this study showed a significant decrease in LDL in the Oligopin supplement group (P =0.011), compared with the placebo group. Moreover, the level of HDL was not significantly different in the supplement group (P=0.651).

Based on the results, the daily concomitant consumption of 100 mg of Oligopin supplement for 6 weeks as adjunctive therapy was effective on LDL; however, no significant effect was observed on HDL in this regard.